Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects.

Citation:
Abd El Aal, H. A., L. A. Ahmed, W. A. Hassan, H. M. Fawzy, and H. Moawad, "Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects.", Journal of biochemical and molecular toxicology, vol. 31, issue 12, 2017 Dec.

Abstract:

The present investigation was designed to examine the possible additive hypolipidemic effect of carvacrol (CARV) in combination with simvastatin (SIM) on poloxamer 407 (P407)-induced hyperlipidemia. Rats were injected with P407, (500 mg/ kg; i.p.), twice a week, for 30 days. Treatment was carried out by administration of SIM (20 mg/kg/day; p.o.) or CARV (50 mg/kg/day; p.o.) or combination of them. Treatment with CARV significantly decreased total cholesterol, triglycerides, low-density lipoprotein, atherogenic index, leptin, and increased high-density lipoprotein and adiponectin. Moreover, CARV potentiated the hypolipidemic effect of SIM. Both SIM and CARV alleviated the oxidative stress induced by P407. Interestingly, CARV, when combined with SIM, significantly ameliorated SIM-induced liver and muscle injury by reducing the level of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, and myoglobin and restoring the normal histological picture of both liver and muscle as well as apoptosis.